Combination
antiviral
therapy
may
be
helpful
in
the
treatment
of
SARS-CoV-2
infection,
however
no
clinical
trial
data
are
available
and
combined
use
direct
acting
antivirals
(DAA)
monoclonal
antibodies
(mAb)
has
been
reported
only
anecdotally.
To
assess
cooperative
effects
dual
drug
combinations
vitro,
we
used
a
VERO
E6
cell
based
vitro
system
with
ancestral
B.1
or
highly
divergent
BQ.1.1
virus
to
test
pairwise
licensed
DAA,
including
nirmatrelvir
(NRM),
remdesivir
(RDV)
active
metabolite
molnupiravir
(EIDD-1931)
as
well
combination
RDV
four
mAbs
(sotrovimab,
bebtelovimab,
cilgavimab,
tixagevimab;
tested
susceptible
virus).
According
SynergyFinder
3.0
summary
weighted
scores,
all
had
an
additive
effect.
Within
DAA/DAA
combinations,
paired
scores
variants
were
comparable.
In
post-hoc
analysis
weighting
synergy
by
concentrations,
several
cases
synergistic
detected
at
specific
both
for
RDV/mAb
combinations.
This
was
supported
confirmation
experiments
showing
more
than
linear
shift
effective
concentration
(IC50)
increasing
concentrations
companion
drug,
although
effect
prominent
but
minimal
null
These
results
support
which
should
further
investigated
animal
models
before
introduction
into
clinic.
Antibodies,
Journal Year:
2024,
Volume and Issue:
13(1), P. 6 - 6
Published: Jan. 5, 2024
Saliva
is
a
promising
matrix
with
several
purposes.
Our
aim
to
verify
if
salivary
anti-SARS-CoV-2
antibody
determination
suitable
for
monitoring
immune
responses.
One
hundred
eighty-seven
subjects
were
enrolled
at
University-Hospital
Padova:
105
females
(56.1%)
and
82
males
(43.9%),
95
(50.8%)
children
92
(49.2%)
adults.
Subjects
self-collected
saliva
using
Salivette;
nineteen
collected
three
different
samples
within
the
day.
A
serum
sample
was
obtained
all
individuals.
The
N/S
IgG
(sal-IgG)
S-RBD
(ser-IgG)
used
determining
antibodies.
mean
(min-max)
age
9.0
(1-18)
42.5
(20-61)
Of
187
samples,
63
negative
sal-IgG
(33.7%),
while
7
ser-IgG
(3.7%).
Spearman's
correlation
0.56
(
medRxiv (Cold Spring Harbor Laboratory),
Journal Year:
2024,
Volume and Issue:
unknown
Published: March 15, 2024
ABSTRACT
An
economic
evaluation
was
conducted
to
predict
the
and
clinical
burden
of
vaccinating
immunocompromised
(IC)
individuals
aged
≥30
years
with
mRNA-1273
variant-adapted
COVID-19
vaccines
in
Fall
2023
Spring
2024
versus
BNT162b2
France.
The
number
symptomatic
infections,
hospitalizations,
deaths,
long
COVID
cases,
costs
quality-adjusted
life
(QALYs)
estimated
using
a
static
decision-analytic
model.
Predicted
vaccine
effectiveness
(VE)
were
based
on
real-world
data
from
prior
versions,
suggesting
higher
protection
against
infection
hospitalization
vaccines.
VE
estimates
combined
incidence
probability
severe
outcomes.
Uncertainty
surrounding
VE,
coverage,
incidence,
mortality
rates,
QALYs
tested
sensitivity
analyses.
is
predicted
prevent
an
additional
3,882
357
81
326
cases
when
compared
230,000
IC
individuals.
This
translates
€10.1
million
cost-savings
societal
perspective
645
saved.
Results
consistent
across
all
analyses
most
sensitive
variations
coverage.
These
findings
highlight
importance
increasing
ability
induce
levels
formulations
this
vulnerable
population.
RSC Advances,
Journal Year:
2024,
Volume and Issue:
14(46), P. 33919 - 33940
Published: Jan. 1, 2024
In
this
post-new-normal
era,
the
public
prioritizes
preventive
measures
over
curing,
which
is
a
constructive
approach
to
staying
healthy.
study,
an
innovative
antimicrobial
membrane
material
has
been
developed,
showcasing
promising
potential
for
various
applications.
The
metal-doped
silica
nanoparticles
(Ag,
Cu,
and
Co)
were
incorporated
into
cellulose
acetate
(CA)
polymer-based
nanofiber
using
electrospinning
technique.
metal
doped
silanol
network
of
nanoparticles.
fabricated
membranes
underwent
detailed
characterization
wide
range
techniques
including
PXRD,
FTIR,
Raman,
SEM,
TEM,
TGA,
tensile
testing.
These
analyses
provided
compelling
evidence
confirming
successful
incorporation
cellulose-based
nanofibers.
band
gap
energies
CA
mats
lie
below
3.00
eV,
that
they
are
visible
light
active.
trimetallic
nanohybrid
exhibited
lowest
energy
2.84
proving
self-sterilizing
ability
mats.
DPPH
assay
further
confirmed
best
radical
scavenging
activity
by
mat
(91.77
±
0.88%).
was
assessed
bacterial
ATCC
strains
Combination
antiviral
therapy
may
be
helpful
in
the
treatment
of
SARS-CoV-2
infection,
however
no
clinical
trial
data
are
available
and
combined
use
direct
acting
antivirals
(DAA)
monoclonal
antibodies
(mAb)
has
been
reported
only
anecdotally.
To
assess
cooperative
effects
dual
drug
combinations
vitro,
we
used
a
VERO
E6
cell
based
vitro
system
with
ancestral
B.1
or
highly
divergent
BQ.1.1
virus
to
test
pairwise
licensed
DAA,
including
nirmatrelvir
(NRM),
remdesivir
(RDV)
active
metabolite
molnupiravir
(EIDD-1931)
as
well
combination
RDV
four
mAbs
(sotrovimab,
bebtelovimab,
cilgavimab,
tixagevimab;
tested
susceptible
virus).
According
SynergyFinder
3.0
summary
weighted
scores,
all
had
an
additive
effect.
Within
DAA/DAA
combinations,
paired
scores
variants
were
comparable.
In
post-hoc
analysis
weighting
synergy
by
concentrations,
several
cases
synergistic
detected
at
specific
both
for
RDV/mAb
combinations.
This
was
supported
confirmation
experiments
showing
more
than
linear
shift
effective
concentration
(IC50)
increasing
concentrations
companion
drug,
although
effect
prominent
but
minimal
null
These
results
support
which
should
further
investigated
animal
models
before
introduction
into
clinic.
